Clinical Trial Comparing Decompression With and Without Coflex™ Interlaminar Technology Treating Lumbar Spinal Stenosis

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

246 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-01-31

Study Completion Date

2014-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A 2 year comparative evaluation of clinical outcome in the treatment of degenerative spinal stenosis with concomitant low back pain by decompression with and without additional stabilization using the coflex® Interlaminar Technology

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Retrospective Evaluation of Performance of Coflex® Interlaminer Technology Versus Decompression With or Without Fusion

NCT03041896

Spinal Stenosis

COMPLETED

Coflex PS3 Actual Conditions for Use Study

NCT02555280

Spinal Stenosis Lumbar

RECRUITING NA

Post-Approval Clinical Trial Comparing the Long Term Safety and Effectiveness Coflex vs. Fusion to Treat Lumbar Spinal Stenosis

NCT00534235

Spinal Stenosis

COMPLETED NA

A Randomized Controlled Trial Comparing Surgical Decompression With an Interlaminar Implant in Patients With Intermittent Neurogenic Claudication Caused by Lumbar Stenosis

NCT01727752

Intermittent Neurogenic Claudication (INC) as a Result of Spinal Stenosis

COMPLETED NA

The Coflex®COMMUNITY Study: An Observational Study of Coflex® Interlaminar Technology

NCT02457468

Spinal Stenosis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The coflex® implant for interlaminar stabilization has been in clinical use for more than 10 years and is CE-certified according to the standards and approved in the United States.

This was a randomized multicenter study to collect prospective data for potential improvement in the therapy of low back pain during the treatment of spinal stenosis. The study was conducted in Germany.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spinal Stenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

coflex™

Implantation of coflex™ device in assigned patients

Group Type ACTIVE_COMPARATOR

Implantation of coflex™ after surgical decompression

Intervention Type DEVICE

The device will be implanted after surgical decompression in patients with spinal stenosis.

Surgical decompression

Surgical decompression in patients with spinal stenosis without stabilization by an additional implant.

Group Type ACTIVE_COMPARATOR

Surgical decompression

Intervention Type PROCEDURE

Surgical decompression in patients with spinal stenosis without stabilization by an additional implant

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Implantation of coflex™ after surgical decompression

The device will be implanted after surgical decompression in patients with spinal stenosis.

Intervention Type DEVICE

Surgical decompression

Surgical decompression in patients with spinal stenosis without stabilization by an additional implant

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Radiographic confirmation of clinical symptoms of at least moderate degenerative spinal stenosis, with constriction of the central spinal canal of one or two adjacent segments in the region L3 to L5 with the need for decompression.

If necessary additional decompression in the adjacent segment(s) may be performed avoiding any instability in the affected segment.

In addition the following may exist (but is not obligatory):
* hypertrophy of the facet joints and subarticular recessus stenosis in the relevant segment or
* stenosis of the foramen in the relevant segment
* and/or stable retrolisthesis up to grade I verified by flexion-/extension X-ray films.
2. Radiographic confirmation of no translatory instability in the main segment as well as in adjacent segments (dynamic translatory instability ≤ 3 mm).
3. VAS back pain score of at least 50 mm on a 100 mm scale (for acute back pain or a period of at least 3 month of back pain before the onset of leg pain).
4. Minimum of 3 months conservative therapy without improvement of symptoms.
5. Age \>40 years.
6. Oswestry Low Back Pain Disability Questionnaire score of at least 18/45 (40%) for German sites or 20/50 (40%) for the US sites (The question about sexual life will be excluded).
7. Suitability of the patient for a posterior surgery procedure.
8. Mental and physical ability of patient to follow the protocol according to compliance to time schedule, treatment plan, fill in of CRF pages and further study procedures.
9. Personally signed informed consent form before the start of any study related procedures.

Exclusion Criteria

Any of the following will exclude a subject from the study:

1. Preceding fusion or decompression surgery of the lumbar spine or preceding nucleotomy of the segments of concern (also if nucleotomy becomes necessary during surgery).
2. Radiographically confirmed damage of the vertebral body in the segment of concern in the lumbar spine (e.g. osteoporotic compression fracture or because of tumors)
3. Isthmic and degenerative spondylolisthesis (anterolisthesis; retrolisthesis \> grade I) or spondylolysis (Pars fracture).
4. Degenerative lumbar scoliosis (\> 25°).
5. Adipositas (obesity). Defined as a body mass index \>40.
6. Pregnancy, or wish to get pregnant during the course of the study.
7. Known allergy for titanium and titanium alloys.
8. Fluoride infections - both systemic and local.
9. History of severe peripheral neuropathy.
10. Significant peripheral vascular disease (claudication intermittens ≥ stage 2b).
11. M. Paget or osteomalacia or other metabolic bone disorders.
12. Cauda equina syndrome.
13. Communicating diseases, including HIV, active hepatitis
14. Patients who are lawfully kept in an institution.
15. Subjects who, in the opinion of the investigator, will be inappropriate for inclusion into this clinical trial or will not comply with requirements of the study.
16. Subjects who participated in a clinical observation or therapy with X-ray during the last 10 years.
17. Subjects who participate(d) in another clinical trial (within the last 4 weeks) that might influence the safety and effectiveness assessment of this trial.

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No